会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明授权
    • Position detecting system and position detecting program
    • 位置检测系统和位置检测程序
    • US08115699B2
    • 2012-02-14
    • US11450451
    • 2006-06-12
    • Shigeru MiyamotoTakao SawanoHitoshi YamazakiShinya Kawada
    • Shigeru MiyamotoTakao SawanoHitoshi YamazakiShinya Kawada
    • G09G5/00
    • G09G5/12G06F3/011G06F3/0304G09G2320/10G09G2354/00G09G2370/00
    • A plurality of positional information transmitters 100, each of which transmits positional information to which a plurality of unit spaces are each uniquely assigned, are disposed on a ceiling. A mobile terminal 10 receives the positional information transmitted from each of the positional information transmitters 100 and changes a terminal-side image in accordance with the received positional information. Furthermore, the mobile terminal 10 transmits to a server 300 current positional information and operation information indicating an instruction inputted by a user. The server 300 changes, in accordance with the current positional information and the operation information received by the mobile terminal 10, a floor image displayed on a plurality of floor displays 200 disposed on a floor. Thus, it becomes possible to provide a highly interesting and novel position detecting system.
    • 多个位置信息发送器100,每个位置信息发送器100发送多个单元间隔被独特地分配给的位置信息。 移动终端10接收从每个位置信息发送器100发送的位置信息,并根据接收到的位置信息改变终端侧图像。 此外,移动终端10向服务器300发送指示用户输入的指示的当前位置信息和操作信息。 服务器300根据当前位置信息和移动终端10接收到的操作信息,改变显示在设置在楼层上的多个楼层显示器200上的楼层图像。 因此,可以提供非常有趣和新颖的位置检测系统。
    • 46. 发明授权
    • Piperazine compounds as inhibitors of MMP or TNF
    • 哌嗪化合物作为MMP或TNF的抑制剂
    • US06489324B2
    • 2002-12-03
    • US09982869
    • 2001-10-22
    • Masahiro NeyaHitoshi YamazakiNatsuko KayakiriKentaro SatoTeruo Oku
    • Masahiro NeyaHitoshi YamazakiNatsuko KayakiriKentaro SatoTeruo Oku
    • C07D24104
    • C07D405/12C07D241/04C07D405/14C07D409/12C07D409/14C07D413/14C07D417/12C07D417/14
    • A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R1 is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R2 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R3 is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substituted lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substituted amino; R4 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R10 is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP-or TNF&agr;-medicated diseases.
    • 式(I)的化合物,其中A是磺酰基或羰基; R1是任选取代的芳基,任选取代的杂环基,任选取代的低级烷基或任选取代的低级烯基; R2是氢,任选取代的低级烷基,任选取代的芳基或任选取代的杂环基; R3是任选取代的低级烷基,任选取代的低级烷氧基,任选取代的芳氧基,任选取代的低级烯基,任选取代的芳基,任选取代的杂环基或任选取代的氨基; R4是氢,任选取代的低级烷基,任选取代的芳基或任选取代的杂环基; R5是氢,任选取代的低级烷基,任选取代的芳基或任选取代的杂环基; R 10为羟基或被保护的羟基及其药学上可接受的盐。 本发明的化合物可用作用于预防和治疗MMP或TNFα药物疾病的药物。